NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company said site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.
NanoViricides said the trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. The company also noted that NV-387, a broad-spectrum antiviral candidate, has been proposed for evaluation against Ebola virus infections and that the shipment makes the drug locally available should it be utilized in response efforts. NanoViricides believes successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola.
The shipment marks a critical milestone for NanoViricides as it advances NV-387 into human trials. The drug candidate is based on the company's nanoviricide platform, which uses specially designed nanomaterials to target viruses. NV-387 is also being developed for respiratory syncytial virus (RSV), COVID-19, influenza, and other viral infections. The company has previously reported positive preclinical data for NV-387 against multiple viruses, including coronaviruses and influenza.
The DRC is currently facing a significant MPox outbreak, with the Clade I strain associated with higher mortality rates than the Clade II strain that caused the 2022 global outbreak. The World Health Organization has declared MPox a public health emergency of international concern, underscoring the need for effective treatments. If NV-387 proves safe and effective in this trial, it could become a vital tool in controlling the outbreak and reducing mortality.
NanoViricides' approach involves creating nanomicelles that mimic host cell receptors, tricking viruses into binding to the drug instead of cells. This mechanism is designed to work against a broad range of viruses, making NV-387 a potential pan-antiviral therapy. The successful development of NV-387 could revolutionize antiviral treatment by providing a single drug effective against multiple viral diseases, reducing the need for virus-specific drugs.
The company also has a pipeline of other drug candidates, including NV-HHV-1 for shingles, and is exploring treatments for HIV, hepatitis, dengue, and Ebola. The shipment to the DRC positions NanoViricides to rapidly respond to emerging viral threats and underscores the importance of broad-spectrum antivirals in pandemic preparedness.
For more information, visit the company's newsroom at https://ibn.fm/NNVC.
